Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04907799
Other study ID # 21-2999
Secondary ID R01DK129259
Status Recruiting
Phase N/A
First received
Last updated
Start date November 3, 2021
Est. completion date July 1, 2026

Study information

Verified date March 2024
Source University of Colorado, Denver
Contact Kristen Nowak, PhD, MPH
Phone 303-724-4842
Email Kristen.Nowak@cuanschutz.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial will determine whether a daily-caloric restriction-based weight loss intervention can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat by magnetic resonance imaging. Blood and fat samples will provide insight into biological changes that may contribute to any observed benefits of the intervention.


Description:

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by development and continued growth of numerous fluid-filled renal cysts that ultimately result in renal failure. Similar to the general population, the prevalence of overweight and obesity have been rising in ADPKD patients, effecting about two-thirds of individuals. Adipocytes do not simply act as a fat reservoir, but are active endocrine organs that promote release of pro-inflammatory cytokines, and thus, may be a promising clinical target for ADPKD management. Mounting evidence also suggests that a metabolic defect exists in ADPKD, which likely contributes to cystic epithelial proliferation and subsequent cyst growth. Additionally, the investigators recently reported that overweight and obesity are strong independent predictors of more rapid kidney growth. Collectively, these data suggest that interventions to reduce abdominal adiposity may slow ADPKD progression. Initial results from the investigators' R03-funded pilot and feasibility study support that a 12-month daily caloric restriction (DCR)-based behavioral weight loss intervention in adults with ADPKD and overweight or obesity: 1) is feasible and acceptable; 2) slowed kidney growth (annual %∆ in height-adjusted TKV [htTKV]), which was highly correlated with weight loss; 3) reduced abdominal adiposity; and 4) altered pathways implicated in ADPKD progression and metabolism. These initial results suggest that a DCR-based behavioral weight loss intervention offers a promising strategy to slow ADPKD progression. However, the pilot and feasibility study was limited by a small sample size, relatively short duration, and lack of a control group. Thus, to translate these promising results of the pilot study towards clinical practice, the investigators are conducting a randomized, controlled clinical trial in a larger number of adults with ADPKD and overweight or obesity to directly compare the efficacy of a DCR-based behavioral weight loss intervention compared to control for slowing kidney growth (primary outcome) over a longer duration. Changes in abdominal adiposity will serve as a secondary outcome and effects of weight loss on circulating and adipose markers of biological pathways will provide mechanistic insight. In a subset of participants recruited for this clinical trial, we will measure change in kidney oxidative metabolism, insulin sensitivity, plasma metabolomics, and gut microbiota. These additional measures will aim to compare kidney oxidative metabolism, insulin sensitivity, plasma metabolome and gut microbiota at baseline and 2 years. In addition, the investigators aim to define the relations among changes in kidney oxidative metabolism, insulin sensitivity, plasma metabolome, gut microbiota, total kidney volume, and body weight over 2 years. Currently, it is unknown if weight loss via DCR modifies renal energy expenditure, substrate utilization, plasma metabolomics, or the gut microbiome.


Recruitment information / eligibility

Status Recruiting
Enrollment 126
Est. completion date July 1, 2026
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - 18-65 years of age - ADPKD diagnosis based on the modified Pei-Ravine criteria - Body-mass index of 25-45 kg/m^2 - Estimated glomerular filtration rate = 30 mL/min/1.73m^2 - Total kidney volume (htTKV) > 600 mL, calculated from a previous kidney ultrasound or magnetic resonance imaging performed within the last 12 months - Access to the internet with video chat capabilities - No plans for extended travel (>2 weeks) without internet access during the 12-month intensive period - Not currently participating in or planning to participate in any formal weight loss or physical activity program, or another interventional study - Ability to provide informed consent Exclusion Criteria: - Diabetes mellitus - Current smokers or history of smoking in the past 12 months - Alcohol dependence or abuse - History of hospitalization or major surgery within the last 3 months - Untreated dyslipidemia - Uncontrolled hypertension - Pregnancy, lactation, or unwillingness to use adequate birth control - Cardiovascular disease, peripheral vascular disease, or symptoms suggestive of cardiovascular disease: chest pain, shortness of breath at rest or with mild exertion, syncope - Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal premature ventricular contractions (PVC's), frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc interval > 480 msec or other significant conduction defects - Significant pulmonary disease including: chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, or uncontrolled asthma - Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism - History of clinically diagnosed eating disorder including: anorexia nervosa, bulimia, binge eating disorder - Weight loss of >5% in the past 3 months for any reason except post-partum weight loss; weight gain >5% requires assessment by PI - Major psychiatric disorder (e.g., psychosis, schizophrenia, mania, bipolar disorder) or current severe depression, based on DSM-IV-TR criteria for Major Depressive Episode, which in the opinion of the Study MD would interfere with ability to adhere to dietary interventions) - Inability to cooperate with or clinical contraindication for magnetic resonance imaging, including: severe claustrophobia, implants, devices, or non-removable body piercings - Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed > 1 year before screening, (2) lap banding if the band has been removed > 1 year before screening, (3) intragastric balloon if the balloon has been removed > 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed > 1 year before screening.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Daily caloric restriction
Weight loss based on daily caloric restriction and increased physical activity
Other:
Standard advice control
Initial nutrition consultation without subsequent counseling

Locations

Country Name City State
United States University of Colorado - Anschutz Medical Campus Aurora Colorado

Sponsors (3)

Lead Sponsor Collaborator
University of Colorado, Denver Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Safety (adverse events) Number of participants with treatment-related adverse events in each group as evaluated by the DSMB 24-months
Other Change in dietary Energy Intake Multiple pass 24-hr dietary recalls will be analyzed to evaluate self-reported energy intake Baseline, 1-, 6-, 12-, and 24-months
Other Adherence Self-reported dietary adherence using a 1-10 likert scale (10 is highest adherence) 24 months
Other Tolerability (dropout due to adverse events) Subject dropout due to treatment-emergent adverse events 24 months
Other Change in free-living physical activity Estimated energy expenditure (METs) over a 7-day period will be quantified using the activPAL3 micro. Baseline, 6-, 12- and 24-months
Other Change in percent body fat Percent body fat will be assessed via DEXA scan in a sub-set of participants. Baseline, 24-months
Other Change in plasma choline Plasma choline will be analyzed by high-performance liquid chromatography-tandem mass spectrometry in a sub-set of participants. Baseline, 24-months
Other Change in plasma trimethylamine Plasma trimethylamine will be analyzed by high-performance liquid chromatography-tandem mass spectrometry in a sub-set of participants. Baseline, 24-months
Other Change in plasma trimethylamine-N-oxide Plasma trimethylamine-N-oxide will be analyzed by high-performance liquid chromatography-tandem mass spectrometry in a sub-set of participants. Baseline, 24-months
Primary Change in height-Adjusted Total kidney volume To assess kidney growth, we will measure height-adjusted total kidney volume by magnetic resonance imaging at baseline and 24 months to determine annual percent change. Baseline, 24-months
Secondary Change in abdominal adiposity Abdominal adiposity (subcutaneous, visceral, and total) will be assessed by magnetic resonance imaging. Baseline, 24-months
Secondary Change in the ratio of insulin-like growth factor-1 (IGF-1)/ to GF binding protein-1 Venous blood samples will be analyzed for this mechanistic biomarker Baseline, 12-months, 24-months
Secondary Change in adiponectin (circulating) Venous blood samples will be analyzed for this mechanistic biomarker Baseline, 12-months, 24-months
Secondary Change in leptin (circulating) Venous blood samples will be analyzed for this mechanistic biomarker Baseline, 12-months, 24-months
Secondary Change in intereukin-6 (circulating) Venous blood samples will be analyzed for this mechanistic biomarker Baseline, 12-months, 24-months
Secondary Change in tumor necrosis factor-alpha (circulating) Venous blood samples will be analyzed for this mechanistic biomarker Baseline, 12-months, 24-months
Secondary Change in C-reactive protein (circulating) Venous blood samples will be analyzed for this mechanistic biomarker Baseline, 12-months, 24-months
Secondary Change in peripheral blood mononuclear cell protein expression of pAMPK/AMPK PBMCs will be isolated from whole blood to assess protein expression Baseline, 12-months, 24-months
Secondary Change in peripheral blood mononuclear cell protein expression of pS6K/S6K PBMCs will be isolated from whole blood to assess protein expression Baseline, 12-months, 24-months
Secondary Change in adiponectin (adipose tissue) A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker. Baseline, 24-months
Secondary Change in leptin (adipose tissue) A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker. Baseline, 24-months
Secondary Change in interleukin-6 (adipose tissue) A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker. Baseline, 24-months
Secondary Change in tumor necrosis factor-alpha (adipose tissue) A subcutaneous adipose tissue biopsy will be performed for assessment of this mechanistic biomarker. Baseline, 24-months
Secondary Change in renal oxygen consumption Renal oxygen consumption will be assessed by a PET/CT scan using 11-C acetate in a sub-set of participants Baseline, 24-months
Secondary Change in gut microbiota 16S rRNA gene sequencing will be used for taxonomic characterization of the gut microbiota in a subset of participants. Baseline, 24-months
Secondary Change in plasma metabolome Untargeted plasma metabolomics will be performed using high-performance liquid chromatography-tandem mass spectrometry in a subset of participants. Baseline, 24-months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A